Amylyx Pharmaceuticals stock drops 80% after ALS drug fails late-stage trial

Amylyx Pharmaceuticals shares dropped more than 80% early Friday after the company said its ALS treatment Relyvrio failed a late-stage trial and may be pulled from the market.

Previous post Buy the pound, Bank of America says, as U.K. currency hits seven-month high
Next post Apple’s stock pressure could continue for months, this bull concedes